Management of Peripheral Neuropathy
First-Line Treatment Options
- The American College of Physicians recommends duloxetine (60-120 mg/day) as a first-line treatment for painful peripheral neuropathy, particularly for chemotherapy-induced and diabetic peripheral neuropathy, with a number needed to treat (NNT) of 5.2 for 60 mg/day and 4.9 for 120 mg/day 1, 2
- The American Diabetes Association suggests pregabalin (300-600 mg/day) as an equally effective first-line alternative, particularly for diabetic peripheral neuropathy, with an NNT of 5.99 for 300 mg/day and 4.04 for 600 mg/day 7, 5
- Gabapentin (900-3600 mg/day) is another first-line option with similar efficacy to pregabalin but requires more frequent dosing 7, 3, 5
Second-Line Treatment Options
- Tricyclic antidepressants (TCAs) remain effective but have fallen out of favor due to side effects, with amitriptyline 25-75 mg/day having an NNT of 1.5-3.5 7, 5, 4
- Venlafaxine (150-225 mg/day) can be considered if duloxetine is not tolerated 7, 5
- Tramadol (200-400 mg/day) is a second-line option with dual mechanism as a weak μ-opioid agonist 5
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Management
- For patients actively receiving neurotoxic chemotherapy who develop intolerable neuropathy, discuss dose delaying, dose reduction, or stopping chemotherapy 1
- For established CIPN after chemotherapy completion, duloxetine is the ONLY treatment with strong evidence 1, 6, 3
Diabetic Peripheral Neuropathy Management
- Optimize glycemic control as the foundational intervention, with a target HbA1c of 6-7% 7
- First-line medications for diabetic neuropathy are duloxetine and pregabalin, both FDA-approved for this indication 7
Critical Pitfalls and Caveats
- Elderly patients require special precautions, including starting with lower doses and titrating more slowly, and monitoring for orthostatic hypotension, confusion, and sedation 5, 4
- Strong opioids should generally be avoided due to risks of addiction, constipation, and lack of long-term efficacy data 5, 4